Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640392 | 1.00 | FUCA1 (0.56) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL4640399 | 1.00 | FUCA1 (0.56) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL3272623 | 0.91 | GBA1 (0.65) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL13382323 | 0.91 | GBA1 (0.65) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL10695886 | 0.89 | FUCA1 (0.50) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL500306 | 0.88 | GBA1 (0.49) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL4506217 | 0.88 | GBA1 (0.49) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL500305 | 0.88 | GBA1 (0.49) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL500304 | 0.88 | GBA1 (0.49) | FUCA1GBA1SIGMAR1RORCS1PR1 | |
| SCHEMBL500415 | 0.88 | GBA1 (0.49) | FUCA1GBA1SIGMAR1RORCS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934924-B1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6576642-B2 | Inhibitors of the production of Ig E antibodies, antiallergens | KOWA CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20010039279-A1 | Diamide compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039279-A1 | Diamide compounds and compositions containing the same | HRH4, HRH2, HRH1 | FUCA1 4245/4885GBA1 3149/4885SIGMAR1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.